drugset / Trial / NCT05805891
Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, prospective study on the efficacy and safety of Bortezomib in addition to standard therapy in patients with refractory rheumatoid arthritis.
Timeline
- Start
- 2023-12
- Primary completion
- 2025-06
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 2 mg | Subcutaneous |